Pharmaceutical product license deals for North America have significantly outnumbered those for Europe, even though both continents have seen an increase in transactions. (See Exhibit 1.) There are plenty of reasons for the discrepancy: the US is the world's largest and most profitable market, enjoys free pricing, and is relatively homogenous. Europe, on the other hand, is complex and fragmented, with strict price controls and cumbersome reimbursement systems.
Which isn't to say there aren't plenty of European companies seeking to in-license products in Europe. Yet few offer the...




